Five self-limiting adverse events occurred (famotidine, n=2 (40%); placebo, n=3 (60% ... phase 2 clinical trial of oral famotidine (80 mg three times a day) and deeply profiled the enrolled diverse, ...

This came after AstraZeneca Pharma India presented the proposal for a grant of permission to import and market Osimertinib tablets 40mg and 80 mg (additional indication) along with global clinical ...